Molecular response to aromatase inhibitor treatment in primary breast cancer
Alan Mackay(Institute of Cancer Research), Mitch Dowsett(Institute of Cancer Research), J. Michael Dixon(University of Colorado Denver), Ander Urruticoechea(Osakidetza), Alexey A. Larionov(NHS Lothian), Suzanne Drury(Gender Studies), Kerry Fenwick(Institute of Cancer Research), Alan Ashworth(University of California, San Francisco), Oliver Young(Western General Hospital), Tim Dexter(Institute of Cancer Research), Sharon White(University of Edinburgh), Dean B. Evans(Novartis (Switzerland)), William R. Miller(Houston Methodist)
Cited by 124
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k